Christos Paliompeis

2.1k total citations · 1 hit paper
11 papers, 1.5k citations indexed

About

Christos Paliompeis is a scholar working on Genetics, Hematology and Rheumatology. According to data from OpenAlex, Christos Paliompeis has authored 11 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Genetics, 10 papers in Hematology and 5 papers in Rheumatology. Recurrent topics in Christos Paliompeis's work include Chronic Lymphocytic Leukemia Research (10 papers), Chronic Myeloid Leukemia Treatments (10 papers) and Eosinophilic Disorders and Syndromes (5 papers). Christos Paliompeis is often cited by papers focused on Chronic Lymphocytic Leukemia Research (10 papers), Chronic Myeloid Leukemia Treatments (10 papers) and Eosinophilic Disorders and Syndromes (5 papers). Christos Paliompeis collaborates with scholars based in United Kingdom, France and United States. Christos Paliompeis's co-authors include Dragana Milojković, Alistair Reid, John M. Goldman, Jane F. Apperley, Richard Szydlo, Marco Bua, David Marín, Letizia Foroni, Jamshid S. Khorashad and Kasia Kozlowski and has published in prestigious journals such as Journal of Clinical Oncology, Blood and JAMA Network Open.

In The Last Decade

Christos Paliompeis

11 papers receiving 1.5k citations

Hit Papers

Adherence Is the Critical Factor for Achieving Molecular ... 2010 2026 2015 2020 2010 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib
    2010 674 citations David Marín, Alexandra Bazeos et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Christos Paliompeis United Kingdom 8 1.2k 1.1k 620 181 181 11 1.5k
François-Xavier Mahon France 10 830 0.7× 721 0.6× 368 0.6× 126 0.7× 121 0.7× 11 1.0k
Marco Bua United Kingdom 18 2.3k 1.8× 2.0k 1.8× 1.3k 2.0× 184 1.0× 271 1.5× 32 2.6k
Marzia Salvucci Italy 15 289 0.2× 272 0.2× 51 0.1× 32 0.2× 146 0.8× 27 716
Clarisse Lobo Brazil 12 1.3k 1.0× 1.1k 1.0× 647 1.0× 2 0.0× 145 0.8× 24 1.5k
A H M Heurkens Netherlands 7 410 0.3× 206 0.2× 1.0k 1.6× 9 0.0× 36 0.2× 7 1.1k
Kejal Parikh United States 10 446 0.4× 113 0.1× 18 0.0× 21 0.1× 36 0.2× 40 634
Ida Carmosino Italy 15 587 0.5× 327 0.3× 134 0.2× 1 0.0× 82 0.5× 83 822
Carole Paley United States 22 1.4k 1.2× 1.2k 1.1× 77 0.1× 1 0.0× 44 0.2× 72 2.0k
Jeff H. Lipton Canada 17 820 0.7× 575 0.5× 289 0.5× 106 0.6× 41 1.1k
O. Gisserot France 8 129 0.1× 167 0.1× 61 0.1× 5 0.0× 51 0.3× 54 567

Countries citing papers authored by Christos Paliompeis

Since Specialization
Citations

This map shows the geographic impact of Christos Paliompeis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christos Paliompeis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christos Paliompeis more than expected).

Fields of papers citing papers by Christos Paliompeis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christos Paliompeis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christos Paliompeis. The network helps show where Christos Paliompeis may publish in the future.

Co-authorship network of co-authors of Christos Paliompeis

This figure shows the co-authorship network connecting the top 25 collaborators of Christos Paliompeis. A scholar is included among the top collaborators of Christos Paliompeis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christos Paliompeis. Christos Paliompeis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Aggarwal, Charu, Alex Martínez‐Martí, Margarita Majem, et al.. (2025). Durvalumab Alone or Combined With Novel Agents for Unresectable Stage III Non–Small Cell Lung Cancer. JAMA Network Open. 8(7). e2518440–e2518440. 1 indexed citations
2.
Gerrard, Gareth, Claire Lucas, Dragana Milojković, et al.. (2013). Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies. Blood. 121(14). 2739–2742. 71 indexed citations
3.
Ibrahim, Amr R., Lina Eliasson, Jane F. Apperley, et al.. (2011). Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood. 117(14). 3733–3736. 246 indexed citations
4.
Milojković, Dragana, Amr R. Ibrahim, Letizia Foroni, et al.. (2011). Assessment of BCR-ABL1 Transcript Levels At 3 Months Is the Only Requirement for Predicting Outcome for Patients with Chronic Myeloid Leukemia Treated with Imatinib. Blood. 118(21). 1680–1680. 3 indexed citations
5.
Marín, David, Amr R. Ibrahim, Claire Lucas, et al.. (2011). Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors. Journal of Clinical Oncology. 30(3). 232–238. 328 indexed citations
6.
Milojković, Dragana, Gareth Gerrard, Christos Paliompeis, et al.. (2011). The Natural History of RTQ-PCR Levels After the Achievement of Complete Molecular Remission (CMR): Implications for ‘Stopping' Studies. Blood. 118(21). 605–605. 7 indexed citations
7.
Marín, David, Alexandra Bazeos, François-Xavier Mahon, et al.. (2010). Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib. Journal of Clinical Oncology. 28(14). 2381–2388. 674 indexed citations breakdown →
8.
Marín, David, Jamshid S. Khorashad, Lihui Wang, et al.. (2010). EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors. Blood. 116(26). 6014–6017. 24 indexed citations
9.
Ibrahim, Amr R., Christos Paliompeis, Marco Bua, et al.. (2010). Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy. Blood. 116(25). 5497–5500. 50 indexed citations
10.
Bazeos, A., Jamshid S. Khorashad, François‐Xavier Mahon, et al.. (2009). Long Term Adherence to Imatinib Therapy Is the Critical Factor for Achieving Molecular Responses in Chronic Myeloid Leukemia Patients.. Blood. 114(22). 3290–3290. 15 indexed citations
11.
Milojković, Dragana, Emma Nicholson, Jane F. Apperley, et al.. (2009). Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica. 95(2). 224–231. 80 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by François-Xavier Mahon Breakdown of academic impact, for papers by Marco Bua Breakdown of academic impact, for papers by Marzia Salvucci Breakdown of academic impact, for papers by Clarisse Lobo Breakdown of academic impact, for papers by A H M Heurkens Breakdown of academic impact, for papers by Kejal Parikh Breakdown of academic impact, for papers by Ida Carmosino Breakdown of academic impact, for papers by Carole Paley Breakdown of academic impact, for papers by Jeff H. Lipton Breakdown of academic impact, for papers by O. Gisserot
Rankless by CCL
2026